Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.

Authors :: Teitel JM
Source :: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 1999 Sep; Vol. 5 Suppl 3, pp. 43-9.
Publication Year :: 1999

Subjects :: Blood Coagulation Factors economics
Blood Coagulation Factors immunology
Blood Coagulation Factors standards
Consumer Product Safety
Costs and Cost Analysis
Factor VIIa economics
Factor VIIa standards
Hemophilia A economics
Humans
Recombinant Proteins economics
Recombinant Proteins standards
Recombinant Proteins therapeutic use
Blood Coagulation Factors therapeutic use
Factor VIIa therapeutic use
Hemophilia A drug therapy
Isoantibodies adverse effects

Language :: English
ISSN :: 1351-8216
Volume :: 5 Suppl 3
Database :: MEDLINE
Journal :: Haemophilia : the official journal of the World Federation of Hemophilia
Publication Type :: Academic Journal
Accession number :: 10597387
Full Text :: https://doi.org/10.1046/j.1365-2516.1999.00037.x

Full Text Access

Tools